Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 to focus on central nervous system (CNS) diseases and disorders. Neurana's first drug candidate is tolperisone, which has been shown to be an effective treatment for muscle spasms and spasticity and is commercialized in markets outside of the United States. Clinical studies and commercial usage have shown that tolperisone is safe and efficacious, and that the drug is non-sedating and non-addictive. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital and MagnaSci Ventures.